Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q4 2023 vs. Q3 2023
How the institutions holding Damora Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 22 | 22 | 0 |
| Shares | 5.45M | 3.85M | −1.60M (−29.3%) |
| Value | $3.92M | $2.77M | −$1.15M (−29.3%) |
New holders (4)
Institutions that held Damora Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 96,927 | $69.8K | 0.00% |
| Citadel Advisors LLC | 72,433 | $52.2K | 0.00% |
| Susquehanna International Group, LLP | 27,525 | $19.8K | 0.00% |
| Royal Bank of Canada | 108 | $0 | 0.00% |
Sold out (4)
Institutions that held Damora Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| OrbiMed Advisors LLC | 924,788 | $665.4K |
| Soleus Capital Management, L.P. | 897,657 | $645.9K |
| Laurion Capital Management LP | 88,580 | $63.7K |
| XTX Topco Ltd | 17,307 | $12.5K |